← Human Trials & Peer-Reviewed Studies
Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion
Plain-language guide to PMID 37075254 (2023): crossover randomized controlled trial study of Octreotide and Somatostatin.
Key Facts
- PMID
- 37075254
- Journal
- Clinical nuclear medicine
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Jiang Y et al. (6 authors)
- DOI
- 10.1097/RLU.0000000000004642
What This Study Did, in Plain Language
What Was Tested
Researchers studied Octreotide and Somatostatin in this randomized controlled trial publication.
An Evans blue-modified 177 Lu-labeled octreotate ( 177 Lu-DOTA-EB-TATE) has an extended circulation in the blood, which may make the amino acid infusion unnecessary.
The aim of this study was to evaluate the safety, biodistribution, and dosimetry of 177 Lu-DOTA-EB-TATE with and without amino acid infusion.
Who Took Part
Ten patients with metastatic neuroendocrine tumors were randomly divided into 2 groups.
All patients underwent serial whole-body planar imaging at 1, 24, 96, and 168 hours and SPECT scan at 24 hours after radioligand administration.
How the Study Was Run
The researchers set it up as a randomized and crossover study.
The participants were allocated by chance, so the Octreotide group and the comparison group should start out alike.
In the crossover set-up each of the participants took both Octreotide and the comparison in turn, acting as their own control.
The effect of amino acid infusion on renal uptake was assessed in a crossover randomized setting.
Abdominal CT was performed 2 days before PRRT for SPECT/CT fusion.
The dosimetry was calculated using the HERMES software.
Dosimetry evaluation was compared on a between-group and intrapatient basis.
What Was Measured
PubMed files the paper under topics including Octreotide, Tissue Distribution, Amino Acids, Organometallic Compounds, Radiopharmaceuticals, Somatostatin and Neuroendocrine Tumors.
What This Means in Plain Language
The paper is a randomized and crossover study of Octreotide and Somatostatin.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2023 (Clinical nuclear medicine), a journal based in United States.
More context: the Octreotide compound page and the Somatostatin compound page, all human trials.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.